Form D · Biotechnology
Duet BioTherapeutics Inc.
Pasadena, CA · CIK 0001952143
Offering snapshot reported Oct 31, 2022 · SEC filing
- Reported sold
- $230K Indefinite offering
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 31, 2022 | Initial | $229,873 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-463398
Source: Form D, filed Oct 31, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert J. Gibson | Director |
| Ira Scott Greenspan | Director |
| Raphael Hofstein | Director |
| Alan Horsager | Director, Executive |
| Joshua Lamstein | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
251 South Lake Avenue Suite 800
Pasadena, CA, 91101
Pasadena, CA, 91101